CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Autologous Bone Marrow Mononuclear Cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00859014
NCT00859014Phase 1Completed
CompareCT.gov

Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients

The University of Texas Health Science Center, Houston·interventional·Posted Mar 10, 2009·Updated Jan 1, 2015

In Brief

A Phase 1 clinical trial evaluating Autologous Bone Marrow Mononuclear Cells for Ischemic Stroke. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this research study is to find out if bone marrow treatment (bone marrow aspiration and infusion of stem cells) can be safely used in adults who have recently (within 24-72 hours)suffered an acute ischemic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.3 years ago

Interventions

Autologous Bone Marrow Mononuclear Cellsbiological

Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells